Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Kidney disease manifests clinically as elevated albumin excretion rate (AER), impaired glomerular filtration rate (GFR), or both, and is a cause of substantial morbidity and mortality in type 1 diabetes (T1D). The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study tested whether intensive diabetes therapy (INT) aimed at lowering glucose concentrations as close as safely possible to the normal range reduces the risks of kidney disease and other diabetes complications. RESEARCH DESIGN AND METHODS: In the DCCT, 1,441 participants with T1D were randomly assigned to INT or conventional diabetes therapy (CON) for a mean duration of 6.5 years. Subsequently, participants have been followed for 18 years in the ongoing observational EDIC. Standardized longitudinal measurements of AER, estimated GFR, and blood pressure were made throughout the DCCT/EDIC. RESULTS: During the DCCT, INT reduced the risks of incident microalbuminuria (AER ≥40 mg/24 h) and macroalbuminuria (AER ≥300 mg/24 h) by 39% (95% CI 21–52%) and 54% (29–74%), respectively. During EDIC years 1–8, participants previously assigned to DCCT INT continued to experience lower rates of incident microalbuminuria and macroalbuminuria, with risk reductions of 59% (39–73%) and 84% (67–92%), respectively. Beneficial effects of INT on the development of impaired GFR (sustained estimated GFR <60 mL/min/1.73 m2) and hypertension became evident during combined DCCT/EDIC follow-up, with risk reductions of 50% (18–69%) and 20% (6–21%), respectively, compared with CON. CONCLUSIONS: In the DCCT/EDIC, INT resulted in clinically important, durable reductions in the risks of microalbuminuria, macroalbuminuria, impaired GFR, and hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this section, the focus is on CKD attributed to diabetes in adults, which occurs in 20-40% of people with diabetes (1-4).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In RCTs, targeting lower HbA1c values using glucose-lowering medications has been proven to reduce risks of microvascular diabetes complications (i.e., kidney disease, retinopathy, neuropathy) and, in some studies, also macrovascular diabetes complications (i.e., cardiovascular events).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both T1D or T2D, lower achieved levels of HbA1c < 7% ( < 53 mmol/mol) versus 8% -9% (64 -75 mmol/mol) reduce risk of overall microvascular complications, including nephropathy and retinopathy, and macrovascular complications in some RCTs. 189 -193”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“while the glucose-lowering effects of SGLT2 inhibitors are blunted with eGFR <45 mL/min/1.73m 2 , the kidney and cardiovascular benefits were still seen at eGFR levels as low as 20 mL/min/ 1.73 m 2 even with no significant change in glucose (4,29,31,107,123,127,129,130).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Hyperglycemia is a known risk factor for the development and progression of both DPN and CKD.9–12”
From Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease (2020) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · cited 1×
“A large body of evidence demonstrates that hyperglycemia contributes to the damage of target organs, including the kidney (5).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102 · cited 1×
“The Chronic Kidney Disease Epidemiology Collaboration equation was used to estimate GFR from calibrated serum creatinine, age, sex, and race (13).”
MethodNathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832 · cited 2×
“The DCCT enrolled 1,441 people with T1D from 1983–1989 to determine the effects of INT on the long-term complications of diabetes (7,9).”
BackgroundMethod(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
Andersen, A. R., Christiansen, J. S., Andersen, J. K., Kreiner, S., & Deckert, T. (1983) · Diabetologia · doi:10.1007/bf00284458 · Cited by 1,067 · cited 1×
“In early cohort studies, up to 40% of patients with T1D developed macroalbuminuria (AER $300 mg/24 h), and up to 75% of these patients progressed to end-stage renal disease (ESRD) within 10 years (1,2).”
BackgroundIntensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
The changing natural history of nephropathy in type I Diabetes
Krolewski, A. S., Warram, J. H., Christlieb, A. R., Busick, E. J., & Kahn, C. R. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90284-0 · Cited by 777
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.193 · Cited by 653
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes
The DCCT/EDIC Research Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111732 · Cited by 568
Antihypertensive Therapy in the Presence of Proteinuria
Sarafidis, P. A., Khosla, N., & Bakris, G. L. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.10.014 · Cited by 364
de Boer, I. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.16 · Cited by 351
Orchard, T. J., Secrest, A. M., Miller, R. G., & Costacou, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1860-3 · Cited by 313 · cited 1×
“Moreover, the presence and severity of kidney disease have been consistently and strongly associated with increased risks of cardiovascular disease (CVD) and death (3,4).”
BackgroundMolitch, M. E., Steffes, M., Sun, W., Rutledge, B., Cleary, P., de Boer, I. H., Zinman, B., Lachin, J., & for the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1098 · Cited by 306 · cited 1×
“9%) in subjects with microalbuminuria (20).”
Cleary, P. A., Orchard, T. J., Genuth, S., Wong, N. D., Detrano, R., Backlund, J.-Y. C., Zinman, B., Jacobson, A., Sun, W., Lachin, J. M., et al. (2006) · Diabetes · doi:10.2337/db06-0653 · Cited by 264
Glucose Control and the Renal and Retinal Complications of Insulin-dependent Diabetes
Chase, H. P. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420080075034 · Cited by 256 · cited 13×
“Reproduced with permission from de Boer et al. (14). evidence that early INT alters the clinical course of kidney disease in T1D.”
BackgroundInfluentialCUBN Is a Gene Locus for Albuminuria
Böger, C. A., Chen, M.-H., Tin, A., Olden, M., Köttgen, A., de Boer, I. H., Fuchsberger, C., O'Seaghdha, C. M., Pattaro, C., Teumer, A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010060598 · Cited by 237
de Boer, I. H., Sibley, S. D., Kestenbaum, B., Sampson, J. N., Young, B., Cleary, P. A., Steffes, M. W., Weiss, N. S., & Brunzell, J. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006040394 · Cited by 165
Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus
de Boer, I. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.2 · Cited by 126
Boright, A. P., Paterson, A. D., Mirea, L., Bull, S. B., Mowjoodi, A., Scherer, S. W., Zinman, B., & and the DCCT/EDIC Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.4.1238 · Cited by 100
Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus
Turkbey, E. B., Backlund, J.-Y. C., Genuth, S., Jain, A., Miao, C., Cleary, P. A., Lachin, J. M., Nathan, D. M., van der Geest, R. J., Soliman, E. Z., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.022327 · Cited by 96
Al-Kateb, H., Boright, A. P., Mirea, L., Xie, X., Sutradhar, R., Mowjoodi, A., Bharaj, B., Liu, M., Bucksa, J. M., Arends, V. L., et al. (2008) · Diabetes · doi:10.2337/db07-1059 · Cited by 93
Baseline analysis of renal function in the Diabetes Control and Complications Trial
Molitch, M. E., Steffes, M. W., Cleary, P. A., & Nathan, D. M. (1993) · Kidney International · doi:10.1038/ki.1993.96 · Cited by 81
Lopes-Virella, M. F., Baker, N. L., Hunt, K. J., Cleary, P. A., Klein, R., Virella, G., & the DCCT/EDIC Research Group (2013) · Diabetes Care · doi:10.2337/dc12-2521 · Cited by 80
Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes
de Boer, I. H., Sachs, M. C., Cleary, P. A., Hoofnagle, A. N., Lachin, J. M., Molitch, M. E., Steffes, M. W., Sun, W., Zinman, B., & Brunzell, J. D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2852 · Cited by 66
Younes, N., Cleary, P. A., Steffes, M. W., de Boer, I. H., Molitch, M. E., Rutledge, B. N., Lachin, J. M., & Dahms, W. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07901109 · Cited by 61
Buschur, E., Sarma, A. V., Pietropaolo, M., Dunn, R. L., Braffett, B. H., Cleary, P. A., Cowie, C., Larkin, M. E., Wessells, H., Nathan, D. M., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1890 · Cited by 48
Maahs, D. M., Jalal, D., Chonchol, M., Johnson, R. J., Rewers, M., & Snell-Bergeon, J. K. (2013) · Diabetes Care · doi:10.2337/dc12-2538 · Cited by 44
Lopes-Virella, M. F., Carter, R. E., Baker, N. L., Lachin, J. M., & Virella, G. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr454 · Cited by 42
Orchard, T. J., Sun, W., Cleary, P. A., GENUTH, S. M., Lachin, J. M., McGee, P., Paterson, A. D., Raskin, P., Anbinder, Y., & Levy, A. P. (2013) · Diabetes · doi:10.2337/db13-0256 · Cited by 37
Aortic Distensibility in Type 1 Diabetes
Turkbey, E. B., Redheuil, A. B., Backlund, J. C., Small, A., Cleary, P. A., Lachin, J. M., Lima, J. A. C., & Bluemke, D. A. (2013) · Diabetes Care · doi:10.2337/dc12-0393 · Cited by 33
Kelbæk, H., Jensen, T., Feldt‐Rasmussen, B., Christensen, N. J., Richter, E. A., Deckert, T., & Nielsen, S. (1991) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519109091641 · Cited by 18
Molitch, M. E., Steffes, M. W., Cleary, P. A., & Nathan, D. M. (1993) · Kidney International · Cited by 13
Cited by
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Metadata
- Authors
- de Boer, I. H., & for the DCCT/EDIC Research Group
- Affiliations
- Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, WA
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 24-30
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3867994
- OpenAlex
- W2160388935
- Semantic Scholar
- 0e25853fef3a739d11a78c1cdc288086bfda2756
- Cited by
- 254
- References
- 38
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 20 · 2023: 26 · 2022: 28 · 2021: 20 · 2020: 27 · 2019: 21 · 2018: 16 · 2017: 12 · 2016: 16 · 2015: 27 · 2014: 11 · 2013: 3
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, U01DK094176, U01-DK094157, RC4DK090766, R01DK088762, P30DK017047)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, diabetic nephropathy, urinary albumin excretion rate, microalbuminuria, macroalbuminuria, glomerular filtration rate, intensive diabetes therapy, glycemic control, hypertension, DCCT/EDIC
- MeSH terms
- Adolescent, Adult, Aged, Albuminuria, Blood Glucose, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypertension, Insulin, Kidney, Male, Middle Aged, Risk Factors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.